Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels

S. Sari, Wening Tri Mawanti, Dewi Martalena, E. Listiyaningsih, Rizkyana Avissa, Rini Latifah, W. Sukarya
{"title":"Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels","authors":"S. Sari, Wening Tri Mawanti, Dewi Martalena, E. Listiyaningsih, Rizkyana Avissa, Rini Latifah, W. Sukarya","doi":"10.19106/jmedsci005303202101","DOIUrl":null,"url":null,"abstract":"COVID-19 is caused by the SARS-CoV-2 infection that attacked the human respiratory system. In severe conditions it causes pneumonia, kidney failure, acute respiratory distress syndrome (ARDS) and even death. The SARS-CoV-2 infection triggers the immune cells to secrete an excess of pro-inflammatory cytokines that lead to cytokine storm. It is believed to become one of the mechanisms that cause the ARDS condition. The level of pro-inflammatory cytokines will differ with each case severity. This study aimed to evaluate the profile of pro-inflammatory cytokines in COVID-19 patients with different severity. Therefore, it could be used as a therapeutic approach for cytokine storm conditions. It was a cross sectional study using plasma samples of COVID-19 patients from Jakarta Islamic Hospital Pondok Kopi and Dr. M. Goenawan Partowidigdo Hospital Cisarua Indonesia. The COVID-19 patients with severe (n=20) and mild to moderate (n=25) severity were involved in this study. As a negative control plasma sample from healthy subjects (n=13) was used. Plasma IL-6 levels were measured using the ELISA technique and plasma lymphocyte levels were measured using a hematology analyzer. The results showed that no significant difference between severity and gender was observed (p=0.256). Meanwhile there is a significant difference in IL-6 level between negative control mild-moderate and severe categories (p=0.015). The average IL-6 level in severe categories was higher than mild-moderate and negative control categories with values 105.375 59.75 and 64.577 pg/mL respectively. This result becomes supporting evidence that there is a cytokine storm condition in severe COVID-19 patients. Furthermore, the lymphocyte level in the severe group is significantly lower than the mild to moderate group. This result may indicate lymphocytopenia in the severe group.","PeriodicalId":17474,"journal":{"name":"Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19106/jmedsci005303202101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

COVID-19 is caused by the SARS-CoV-2 infection that attacked the human respiratory system. In severe conditions it causes pneumonia, kidney failure, acute respiratory distress syndrome (ARDS) and even death. The SARS-CoV-2 infection triggers the immune cells to secrete an excess of pro-inflammatory cytokines that lead to cytokine storm. It is believed to become one of the mechanisms that cause the ARDS condition. The level of pro-inflammatory cytokines will differ with each case severity. This study aimed to evaluate the profile of pro-inflammatory cytokines in COVID-19 patients with different severity. Therefore, it could be used as a therapeutic approach for cytokine storm conditions. It was a cross sectional study using plasma samples of COVID-19 patients from Jakarta Islamic Hospital Pondok Kopi and Dr. M. Goenawan Partowidigdo Hospital Cisarua Indonesia. The COVID-19 patients with severe (n=20) and mild to moderate (n=25) severity were involved in this study. As a negative control plasma sample from healthy subjects (n=13) was used. Plasma IL-6 levels were measured using the ELISA technique and plasma lymphocyte levels were measured using a hematology analyzer. The results showed that no significant difference between severity and gender was observed (p=0.256). Meanwhile there is a significant difference in IL-6 level between negative control mild-moderate and severe categories (p=0.015). The average IL-6 level in severe categories was higher than mild-moderate and negative control categories with values 105.375 59.75 and 64.577 pg/mL respectively. This result becomes supporting evidence that there is a cytokine storm condition in severe COVID-19 patients. Furthermore, the lymphocyte level in the severe group is significantly lower than the mild to moderate group. This result may indicate lymphocytopenia in the severe group.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不同严重程度COVID-19患者的促炎细胞因子(IL-6)和淋巴细胞总数
COVID-19是由攻击人类呼吸系统的SARS-CoV-2感染引起的。在严重的情况下,它会导致肺炎、肾衰竭、急性呼吸窘迫综合征(ARDS)甚至死亡。SARS-CoV-2感染触发免疫细胞分泌过量的促炎细胞因子,导致细胞因子风暴。这被认为是导致ARDS的机制之一。促炎细胞因子的水平会随着病情的严重程度而有所不同。本研究旨在评估不同严重程度COVID-19患者的促炎细胞因子特征。因此,它可以作为一种治疗细胞因子风暴的方法。这是一项横断面研究,使用了来自印度尼西亚雅加达伊斯兰医院Pondok Kopi和Dr. M. Goenawan Partowidigdo医院的COVID-19患者的血浆样本。本研究纳入重症(n=20)和轻中度(n=25)的COVID-19患者。阴性对照采用健康受试者(n=13)的血浆样本。采用ELISA技术测定血浆IL-6水平,采用血液学分析仪测定血浆淋巴细胞水平。结果显示,严重程度与性别无显著差异(p=0.256)。阴性对照轻、中度、重度组患者IL-6水平差异有统计学意义(p=0.015)。重度组平均IL-6水平高于轻、中度组和阴性对照组,分别为105.375、59.75和64.577 pg/mL。这一结果成为支持COVID-19重症患者存在细胞因子风暴条件的证据。重度组淋巴细胞水平明显低于轻、中度组。此结果可能提示重症组淋巴细胞减少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Congenital cystic adenomatoid malformation: a case report Prostate cancer profile in Dr. Sardjito General Yogyakarta Risk factors of sensory hearing loss in nasopharyngeal carcinoma patients obtaining conventional radiotherapy Infant appendicitis with perforation: a case report Prevalence of hypertension and its risk factors among obese adolescents in Yogyakarta, Indonesia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1